Y-mabs to participate in upcoming investor conferences in september

New york, sept. 03, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that michael rossi, president and chief executive officer, will present at the following upcoming investor conferences:
YMAB Ratings Summary
YMAB Quant Ranking